Meda acquires global rights to MUSE

Meda acquires global rights to MUSE

Meda today announced the acquisition of global rights to MUSE
(transurethral alprostadil), a well established product for the
treatment of erectile dysfunction.

Meda has had the distribution rights to MUSE in Europe for many years.
Meda will now take over global rights and all assets relating to the
product. The largest market is the US where annual sales are
approximately 15 MUSD.

The acquisition price is an upfront payment of 22 MUSD and a potential
sales milestone payment of 1,5 MUSD based on future sales of MUSE. The
transaction is subject to standard closing requirements. The transaction
is expected to close within 60 days.

 

 

 

 

If questions, please contact: Anders Larnholt, Vice President Corporate
Development & IR ph: +46 709-458 878